Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Melanoma 44Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 14Lung Neoplasms 11Neoplasm Metastasis 10Pancreatic Neoplasms 9Brain Neoplasms 9Neoplasms 8Triple Negative Breast Neoplasms 6Skin Neoplasms 5Colonic Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Multiple Myeloma 3Hematologic Neoplasms 3Glioma 3Gastrointestinal Stromal Tumors 3Breast Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Skin Diseases 2Recurrence 2Neurofibromatosis 1 2Lymphoma 2Leukemia, Hairy Cell 2Hereditary Sensory and Autonomic Neuropathies 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2

Interventions

Sorafenib 3selpercatinib 2cabozantinib 2Thyroid (USP) 2Sodium 2Radiofrequency Ablation 2Metformin 2vandetanib 1tomivosertib 1temsirolimus 1repotrectinib 1pralsetinib 1pembrolizumab 1lenvatinib 1binimetinib 1apatinib 1acetaminophen, codeine drug combination 1Vitamin B 12 1Tramadol 1Thyroxine 1Thyrotropin-Releasing Hormone 1Technetium Tc 99m Sestamibi 1Surgical Procedures, Operative 1Pemetrexed 1Panobinostat 1Negative-Pressure Wound Therapy 1NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt 1Lysine Acetyltransferase 5 1Iodine-131 1Folic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Diseases × binimetinib × Clear all
NCT04913285 2026-04-27

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Pierre Fabre Medicament

Phase 1 Active not recruiting
400 enrolled
DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡